Galectin Therapeutics (GALT) Common Equity (2010 - 2026)

Galectin Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at -$132.0 million for Q1 2026.

• In Q1 2026, Common Equity fell 15.77% year-over-year to -$132.0 million; the TTM figure through Mar 2026 stood at -$132.0 million (down 15.77% YoY), while the FY2025 annual figure was -$127.9 million, down 22.07% from the prior year.
• Common Equity was -$132.0 million for Q1 2026 at Galectin Therapeutics, down from -$127.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$7.9 million in Q1 2022 to a low of -$132.0 million in Q1 2026.
• Historically, Common Equity has averaged -$72.9 million across 5 years, with a median of -$62.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Common Equity tumbled 3898.1% in 2022, then changed 0.0% in 2024.
• A 5-year view of Common Equity shows it stood at -$33.9 million in 2022, then tumbled by 82.69% to -$62.0 million in 2023, then slumped by 69.12% to -$104.8 million in 2024, then slipped by 22.07% to -$127.9 million in 2025, then dropped by 3.16% to -$132.0 million in 2026.
• The last three Common Equity figures came in at -$132.0 million (Q1 2026), -$127.9 million (Q4 2025), and -$125.3 million (Q3 2025), per Business Quant data.